Lifeboat Foundation

Scientists in California tried to study Alzheimer’s disease from a different perspective and the results may have led them to the cause of the disease.

Researchers at the University of California-Riverside (UCR) recently published results from a study that looked at a protein called tau. By studying the different forms tau proteins take, researchers discovered the difference between people who developed dementia and those who didn’t.

The tau protein was critical for researchers because they wanted to understand what the protein could reveal about the mechanism behind plaques and tangles, two critical indicators doctors look for when diagnosing people with Alzheimer’s.

The race to find medical treatments for Covid-19—and future pandemics—is on, driving renewed investments by the healthcare and pharmaceutical industries in Real-World Data (RWD) and Real-World Evidence (RWE). A new report on AI and the real-world studies industry, from Deep Pharma Intelligence (DPI), Evomics Medical and The Yuan (an online forum focused on AI in healthcare, for which I am a contributor), provides fresh insights into this rapidly evolving patient-centric approach to increasing R&D efficiency, accelerating the introduction of new drugs, and improving health outcomes. Full Story:

Circa 2019

Researchers of Sechenov University and University of Pittsburgh described the most promising strategies in applying genetic engineering for studying and treating Parkinson’s disease. This method can help evaluate the role of various cellular processes in pathology progression, develop new drugs and therapies, and estimate their efficacy using animal disease models. The study was published in Free Radical Biology and Medicine.

Parkinson’s disease is a neurodegenerative disorder accompanied by a wide array of motor and cognitive impairments. It develops mostly among elderly people (after the age of 55–60). Parkinson’s symptoms usually begin gradually and get worse over time. As the disease progresses, people may have difficulty controlling their movements, walking and talking and, more importantly, taking care of themselves. Although there is no cure for Parkinson’s disease, medicines, surgical treatment, and other therapies can often relieve some symptoms.

Continue reading “Scientists listed ways of applying genetic engineering to treat Parkinson’s disease” »

Citizen journalist now close to death.

Citizen journalist Zhang Zhan is in a Chinese prison for reporting from Wuhan during the height of the city’s coronavirus outbreak in 2020. Her family says she is on hunger strike and could be near death. All calls for her release have gone unheeded.

Continue reading “China: Citizen journalist Zhang Zhan detained over Wuhan reporting | DW News” »

Researchers have developed a new approach to machine learning that ‘learns how to learn’ and out-performs current machine learning methods for drug design, which in turn could accelerate the search for new disease treatments.

The method, called transformational machine learning (TML), was developed by a team from the UK, Sweden, India and Netherlands. It learns from multiple problems and improves performance while it learns.

TML could accelerate the identification and production of new drugs by improving the machine learning systems which are used to identify them. The results are reported in the Proceedings of the National Academy of Sciences.

There’s also been a lot of interest in creating more versatile “living inks” made up of bacteria, which can be genetically engineered to do everything from deliver drugs to clean up pollutants. But so far, approaches have relied on mixing microbes with polymers that help provide the ink with some structural integrity.

Now, researchers have developed a new living ink that more closely lives up to the name by replacing the polymers with a protein made by genetically engineered E. coli bacteria. The researchers say this opens the door to seeding large-scale, living structures from nothing more than a simple cell culture.

The key to the breakthrough was to repurpose the proteins that E. coli cells secrete to stick together and form hard-to-shift biofilms. In a paper in Nature Communications, the researchers describe how they genetically engineered bacteria to produce two different versions of this protein known as a “knob” and a “hole,” which then lock together to form a robust cross-linked mesh.

The top 10 emerging technologies include self-fertilizing crops, on-demand drug manufacturing, breath-sensing diagnostics and 3D-printed houses. Check the full list of emerging tech.

TRU Community Care in Lafayette was the host to the unveiling of a brand new technology in the medical field — a humanoid robot that can perform basic medical tasks.

Beyond Imagination, an AI company based out of Colorado Springs, visited the Lafayette hospice center to test out the robot, named BEOMNI.

“We are excited that TRU sees the almost limitless potential of our humanoid robots in health care and has agreed to run this first pilot study with us. We look forward to partnering with them to bring a highly effective solution to market,” said inventor and CEO Dr. Harry Kloor.

The mysterious ways cancer spreads through the body, a process known as metastasis, is what can make it such a difficult enemy to keep at bay. Researchers at Princeton University working in this area have been tugging at a particular thread for more than 15 years, focusing on a single gene central to the ability of most major cancers to metastasize. They’ve now discovered what they describe as a “silver bullet” in the form of a compound that can disable this gene in mice and human tissue, with clinical trials possibly not too far away.

Metastatic cancer is a key focus for researchers and with good reason, as it is actually the primary cause of death from the disease. While surgery or chemotherapy might be effective at eliminating an initial tumor, cells that have broken away can discreetly make their way around the body and give rise to new tumors, months or even years later.

“Metastatic breast cancer causes more than 40,000 deaths every year in the US, and the patients do not respond well to standard treatments, such as chemotherapies, targeted therapies and immunotherapies,” says Minhong Shen, member of the Princeton team behind the new discovery. “Our work identified a series of chemical compounds that could significantly enhance the chemotherapy and immunotherapy response rates in metastatic breast cancer mouse models. These compounds have great therapeutic potential.”